BioSpace News Archive

On July 10, 2019, CStone announced the dosing of the first patient in China for the VOYAGER trial.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the commencement of an underwritten secondary offering of 1,200,000 shares of Madrigal’s common stock by investment funds affiliated with Bay City Capital LLC.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2020 before the market open on Tuesday, January 7, 2020.

Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock.

Select Medical Holdings Corporation (“Holdings”) (NYSE: SEM), today announced that Select Medical Corporation (“Select”) has completed its private placement of $675 million aggregate principal amount of its 6.250% Senior Notes due 2026 as additional notes (the “Additional Notes”)

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Bone Bank Allografts (BBA), a leading provider of regenerative medicine technologies to the surgical community, announced a multi-year partnership agreement with Yankee Alliance, a group purchasing organization (GPO) with more than 15,000 members across the United States.

Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) met to review the Company’s New Drug Application (NDA) seeking approval for Brinavess.

Precision Castparts Corp., a global manufacturer of complex metal components and products for critical aerospace and industrial markets, will invest $128 million in a new R&D engineering lab and manufacturing center in Mason, OH

The legislative proposal fails to eliminate rate-setting provision and arbitrary threshold for independent dispute resolution.